A meta-analysis of randomized controlled trials in patients with clinically diagnosed depression or anxiety found that probiotic supplementation reduced symptoms compared with placebo. The Oxford-led review, published in Nutrition Reviews in December 2024, pooled data from 23 trials and about 1,400 participants.
For depression, the standardized mean difference favored probiotics by -0.96, a large effect on paper. For anxiety, the pooled difference was -0.59, a moderate reduction.
The trials tested a familiar cast of bacteria. Lactobacillus species such as L. acidophilus, L. helveticus and L. rhamnosus, and Bifidobacterium species including B. longum, B. breve and B. bifidum, showed up most often.
Treatment ran from three to 24 weeks, with four to 12 weeks the most common. Shorter courses under eight weeks actually produced larger reductions in depression symptoms than longer ones.
Also read: Two common sleep problems may be early warning signs of Parkinson's and other brain diseases
Why the gut may talk to the brain
The gut and brain communicate along several pathways, sometimes called the gut-brain axis. A 2025 review in Frontiers in Microbiology points to vagus-nerve signaling, hormone shifts along the HPA axis, immune activity, and metabolic byproducts as the main routes.
People with depression often show fewer beneficial bacteria from the Lactobacillus and Bifidobacterium groups. That biological plausibility helps explain why so many trials have been mounted.
But the same review is candid. Results across studies are inconsistent, and one earlier meta-analysis found no significant benefit for anxiety at all. The authors call for strain-specific work rather than blanket claims about probiotics.
What the trials still cannot answer
The headline numbers from the Oxford-led meta-analysis look strong, but the fine print matters. Heterogeneity across the 23 trials was very high.
Also read: Your calcium and vitamin D supplements may not be protecting your bones at all
When the reviewers excluded seven studies judged at high risk of bias, the pooled effect on depression shrank by nearly a third. They also documented substantial publication bias and downgraded their overall certainty of evidence for depression to low, and for anxiety to moderate.
There is no agreement on the right strain, dose, or duration. Doses in the trials ranged from about 10 million to 10 billion colony-forming units per dose.
Single-strain formulas actually appeared to work better than multi-strain blends, an inversion of much marketing copy. Most trials were small and predominantly enrolled women, which limits how broadly the results can be applied.
The reviewers position probiotics as a possible adjunct to standard treatment, not a substitute. People with symptoms of depression or anxiety should speak to a clinician before adding or changing anything they take.
Also read: For depression and anxiety, one type of exercise consistently outperforms the rest
Broader safety data from the National Center for Complementary and Integrative Health note that harmful effects, though uncommon in healthy adults, are more likely in people with severe illness or weakened immune systems.
For now, the honest answer is the one the trials keep pointing to. Certain probiotic strains, taken for a few weeks, may nudge symptoms downward in some patients on top of usual care. That is a useful signal, not yet a prescription.
Also read: Too little sleep rivaled smoking as a predictor of how long people live